Daniel Geffken

Daniel Geffken has over 10 years of experience in the life sciences industry. In 2011, they founded and became the Managing Director of Danforth Advisors, a company that provides specialized services in finance, accounting, and operations for life science companies. In 2020, they became the Chief Financial Officer of Locust Walk Acquisition Corp. and in 2021, they became the Interim Chief Financial Officer of Bionaut Labs and Eloxx Pharmaceuticals, and the Senior Financial Advisor of Olaris, Inc., Affini-T, Myeloid Therapeutics, Acrivon Therapeutics, Inc., and Century Therapeutics, LLC. Daniel also became the Interim Chief Financial Officer of CalciMedica in 2020.

Daniel Geffken obtained their MBA from Harvard Business School between 1985 and 1987. Daniel also earned a B.S. in Economics from The Wharton School between 1975 and 1979, with a focus in Economics.